5 Healthcare Stocks Insiders Are Buying

4. Veradermics, Incorporated (NYSE:MANE)

On March 30, 2026, Veradermics, Incorporated (NYSE:MANE) reported a Q4 net loss of $21.8M and ended the year with $141.9M in cash, cash equivalents, and marketable securities. CEO Reid Waldman said 2025 was a “landmark year,” highlighting progress in Phase 3 development of VDPHL01 and the company’s IPO, while noting expectations for two Phase 3 readouts in men, continued progress toward an NDA submission, and advancement of a Phase 3 trial for female pattern hair loss.

Earlier in March, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Overweight rating, noting the company’s focus on dermatology and its use of “validated biology” of minoxidil with optimized pharmacokinetics to improve efficacy and safety.

Similarly, Leerink initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Outperform rating and a $75 price target, highlighting the large market for hair loss treatments and positioning VDPHL01 as a potential best-in-class oral therapy for both men and women, supported by a hybrid marketing strategy combining telehealth and direct access.

Veradermics, Incorporated (NYSE:MANE) develops therapies for dermatologic and aesthetic conditions.